Regardless, in a Delphi Consensus comprising of global experts in the ART field, 100% of experts surveys agreed that a GnRH agonist trigger, in a GnRH antagonist protocol, should be used for final oocyte maturation in women at risk of OHSS (30). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.